COMPASS PATHWAYS PLC Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
COMPASS PATHWAYS PLC (CMPS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $1.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $1.88M, a 494.32% increase year-over-year.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $317.00K.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$45.00K, a 106.76% decline year-over-year.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $666.00K.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $1.04M, a 438.66% increase from fiscal 2024.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $194.00K, a 77.62% decline from fiscal 2023.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $867.00K.
- COMPASS PATHWAYS PLC effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$24.96M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.96M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $1.88M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.04M 10-K · filed 2026-03-24 | |||
| 2025-09-30 | -$227.00K 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $611.00K 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $317.00K 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $194.00K 10-K · filed 2026-03-24 | |||
| 2024-09-30 | $464.00K 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$99.00K 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -$45.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $867.00K 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $857.00K 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $678.00K 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $666.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$24.96M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | -$39.88M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$24.85M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$6.54M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$5.58M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$6.52M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $1.85M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $2.08M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $13.22M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $2.63M 6-K · filed 2021-11-09 | |||
| 2020-06-30 | -$1.94M 6-K · filed 2021-08-11 | |||
| 2019-12-31 | $1.68M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |